Gabelli Funds LLC Has $32.63 Million Position in Boston Scientific Corporation $BSX

Key Points

• Gabelli Funds LLC reduced its holdings in Boston Scientific by 18.2%, now holding 323,471 shares valued at approximately $32.63 million.
• Several research firms have upgraded their ratings for Boston Scientific, with UBS Group raising the price target from $130.00 to $135.00, indicating a bullish sentiment among analysts.
• Boston Scientific reported a 22.8% increase in revenue year-over-year, with earnings per share surpassing analysts' expectations at $0.75 for the last quarter.

Gabelli Funds LLC decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 18.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 323,471 shares of the medical equipment provider's stock after selling 72,125 shares during the period. Gabelli Funds LLC's holdings in Boston Scientific were worth $32,632,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BSX. Colonial Trust Co SC boosted its holdings in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares during the period. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific in the fourth quarter worth about $25,000. Sunbeam Capital Management LLC acquired a new position in shares of Boston Scientific in the fourth quarter worth about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the first quarter worth about $27,000. Finally, Ameriflex Group Inc. acquired a new position in shares of Boston Scientific in the fourth quarter worth about $31,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded down $0.19 during midday trading on Friday, hitting $105.56. The company had a trading volume of 4,066,860 shares, compared to its average volume of 7,483,689. The business's 50 day simple moving average is $104.45 and its two-hundred day simple moving average is $102.17. The stock has a market cap of $156.41 billion, a PE ratio of 62.83, a P/E/G ratio of 2.55 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1-year low of $79.53 and a 1-year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the sale, the chief executive officer owned 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 345,029 shares of company stock worth $35,976,603. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BSX. Robert W. Baird upped their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Needham & Company LLC reiterated a "buy" rating and issued a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. UBS Group raised their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Morgan Stanley raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Finally, Citigroup reaffirmed a "buy" rating and set a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.